Hepatocellular cystathionine γ lyase/hydrogen sulfide attenuates nonalcoholic fatty liver disease by activating farnesoid X receptor

Wenjing Xu, Changting Cui, Chunmei Cui, Zhenzhen Chen, Haizeng Zhang, Qinghua Cui, Guoheng Xu, Jianglin Fan, Yu Han, Liangjie Tang, Giovanni Targher, Christopher D. Byrne, Ming‐Hua Zheng, Liming Yang, Jun Cai, Bin Geng – 18 May 2022

Impact of major hepatocellular carcinoma policy changes on liver transplantation for hepatocellular carcinoma in the United States

Rahil H. Shah, Darius Chyou, David S. Goldberg – 17 May 2022 – Since its inception in 2002, Model for End‐Stage Liver Disease (MELD)–based allocation has undergone a series of revisions, especially with respect to exception points. Hepatocellular carcinoma (HCC) is the most common indication for MELD exceptions, and as a result of higher transplant proportions and lower waitlist mortality, a series of policy changes have been implemented to deprioritize HCC transplants. We examined the impact of HCC exception policy changes on transplant and waitlist mortality rates.

Liver transplantation of partial grafts after ex situ splitting during hypothermic oxygenated perfusion—The HOPE–Split pilot study

Guillaume Rossignol, Xavier Muller, Valérie Hervieu, Sophie Collardeau‐Frachon, Antoine Breton, Natacha Boulanger, Mickaël Lesurtel, Rémi Dubois, Kayvan Mohkam, Jean‐Yves Mabrut – 17 May 2022 – Partial liver grafts from ex situ splitting are considered marginal due to prolonged static cold storage. The use of ex situ hypothermic oxygenated perfusion (HOPE) may offer a strategy to improve preservation of ex situ split grafts.

Subscribe to